Ost-müük Gilead Sciences - GILD CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.14 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Gilead Sciences Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 79.13 |
| Avatud* | 79.08 |
| Aastane muutus* | 32.68% |
| Päeva ulatus* | 78.21 - 79.16 |
| 52 nädala ulatus | 57.17-89.74 |
| Keskmine maht (10 päeva) | 6.97M |
| Keskmine maht (3 kuud) | 127.33M |
| Turukapitalisatsioon | 99.10B |
| P/E suhtarv | 21.84 |
| Ringluses olevad aktsiad | 1.25B |
| Tulu | 27.28B |
| EPS | 3.64 |
| Dividendid (% kasumist) | 3.77548 |
| Beeta | 0.40 |
| Järgmine tuluaruande kuupäev | Apr 26, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2023 | 78.29 | -0.99 | -1.25% | 79.28 | 79.96 | 78.29 |
| Mar 20, 2023 | 78.82 | 2.26 | 2.95% | 76.56 | 79.59 | 76.14 |
| Mar 17, 2023 | 77.23 | -2.28 | -2.87% | 79.51 | 79.78 | 76.46 |
| Mar 16, 2023 | 78.98 | 0.19 | 0.24% | 78.79 | 79.88 | 77.74 |
| Mar 15, 2023 | 78.98 | -0.65 | -0.82% | 79.63 | 79.82 | 78.03 |
| Mar 14, 2023 | 78.62 | -0.12 | -0.15% | 78.74 | 79.83 | 78.24 |
| Mar 13, 2023 | 79.28 | -0.26 | -0.33% | 79.54 | 81.19 | 76.94 |
| Mar 10, 2023 | 79.00 | 0.48 | 0.61% | 78.52 | 80.24 | 77.61 |
| Mar 9, 2023 | 78.90 | -0.83 | -1.04% | 79.73 | 80.58 | 78.22 |
| Mar 8, 2023 | 79.73 | -0.36 | -0.45% | 80.09 | 80.68 | 79.48 |
| Mar 7, 2023 | 79.79 | -0.94 | -1.16% | 80.73 | 81.23 | 79.79 |
| Mar 6, 2023 | 81.04 | 0.27 | 0.33% | 80.77 | 81.25 | 80.35 |
| Mar 3, 2023 | 80.57 | 1.14 | 1.44% | 79.43 | 81.09 | 79.03 |
| Mar 2, 2023 | 79.43 | -0.05 | -0.06% | 79.48 | 79.83 | 78.44 |
| Mar 1, 2023 | 79.31 | -0.98 | -1.22% | 80.29 | 80.58 | 78.93 |
| Feb 28, 2023 | 79.96 | -0.55 | -0.68% | 80.51 | 80.92 | 79.28 |
| Feb 27, 2023 | 80.53 | 0.05 | 0.06% | 80.48 | 81.24 | 79.61 |
| Feb 24, 2023 | 80.59 | -1.69 | -2.05% | 82.28 | 82.49 | 80.13 |
| Feb 23, 2023 | 82.19 | -0.74 | -0.89% | 82.93 | 83.77 | 82.10 |
| Feb 22, 2023 | 82.93 | -1.75 | -2.07% | 84.68 | 84.83 | 82.93 |
Gilead Sciences Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 27305 | 24689 | 22449 | 22127 | 26107 |
| Tulu | 27305 | 24689 | 22449 | 22127 | 26107 |
| Kulud, Kokku | 6601 | 4572 | 4675 | 4853 | 4371 |
| Brutokasum | 20704 | 20117 | 17774 | 17274 | 21736 |
| Kogu tegevuskulu | 17387 | 20618 | 18162 | 13927 | 11983 |
| Müük/Üldine/admin kulud, kokku | 5246 | 5151 | 4381 | 4056 | 3830 |
| Uuringud ja arendus | 5540 | 10895 | 8934 | 4846 | 3512 |
| Ootamatud kulutused (tulu) | 172 | 172 | 270 | ||
| Tulud majandustegevusest | 9918 | 4071 | 4287 | 8200 | 14124 |
| Intressitulud (kulu), muud tulud, neto | -1611 | -2684 | 227 | -964 | -1190 |
| Muud, neto | -29 | 282 | 646 | 563 | 595 |
| Netotulu enne makse | 8278 | 1669 | 5160 | 7799 | 13529 |
| Netotulu pärast makse | 6201 | 89 | 5364 | 5464 | 10136 |
| Vähemuse intress | 24 | 34 | 22 | -5 | -16 |
| Netotulu enne erikulusid | 6225 | 123 | 5386 | 5459 | 10120 |
| Netotulu | 6225 | 123 | 5386 | 5455 | 4628 |
| Arvestatav tulu, v a erikulud | 6225 | 123 | 5386 | 5459 | 10120 |
| Arvestatav tulu, koos erikuludega | 6225 | 123 | 5386 | 5455 | 4628 |
| Jaotuse korrigeerimine | |||||
| Jaotamisele kuuluv netotulu | 6225 | 123 | 5386 | 5455 | 4628 |
| Keskmine jaotamisele kuuluv aktsia kohta | 1262 | 1263 | 1277 | 1308 | 1319 |
| Jaotatav EPS, v a erakorralised kulud | 4.93265 | 0.09739 | 4.2177 | 4.17355 | 7.67248 |
| Dividends per Share - Common Stock Primary Issue | 2.84 | 2.72 | 2.52 | 2.28 | 2.08 |
| Jaotamisele kuuluv normaal-EPS | 4.93265 | 0.09739 | 4.30525 | 4.26568 | 7.82584 |
| Erakorralised kulud kokku | -4 | -5492 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 6590 | 7244 | 7421 | 6217 | 6423 |
| Tulu | 6590 | 7244 | 7421 | 6217 | 6423 |
| Kulud, Kokku | 1424 | 2627 | 1223 | 1390 | 1361 |
| Brutokasum | 5166 | 4617 | 6198 | 4827 | 5062 |
| Kogu tegevuskulu | 6393 | 6304 | 3579 | 3971 | 3533 |
| Müük/Üldine/admin kulud, kokku | 1083 | 1650 | 1190 | 1351 | 1044 |
| Uuringud ja arendus | 1186 | 2027 | 1166 | 1230 | 1117 |
| Ootamatud kulutused (tulu) | 2700 | 11 | |||
| Tulud majandustegevusest | 197 | 940 | 3842 | 2246 | 2890 |
| Intressitulud (kulu), muud tulud, neto | -334 | -181 | -392 | -430 | -608 |
| Muud, neto | -15 | -12 | 1 | -18 | |
| Netotulu enne makse | -152 | 759 | 3438 | 1817 | 2264 |
| Netotulu pärast makse | 12 | 376 | 2586 | 1517 | 1722 |
| Vähemuse intress | 7 | 6 | 6 | 5 | 7 |
| Netotulu enne erikulusid | 19 | 382 | 2592 | 1522 | 1729 |
| Netotulu | 19 | 382 | 2592 | 1522 | 1729 |
| Arvestatav tulu, v a erikulud | 19 | 382 | 2592 | 1522 | 1729 |
| Arvestatav tulu, koos erikuludega | 19 | 382 | 2592 | 1522 | 1729 |
| Jaotamisele kuuluv netotulu | 19 | 382 | 2592 | 1522 | 1729 |
| Keskmine jaotamisele kuuluv aktsia kohta | 1262 | 1262 | 1262 | 1260 | 1262 |
| Jaotatav EPS, v a erakorralised kulud | 0.01506 | 0.30269 | 2.05388 | 1.20794 | 1.37005 |
| Dividends per Share - Common Stock Primary Issue | 0.73 | 0.71 | 0.71 | 0.71 | 0.71 |
| Jaotamisele kuuluv normaal-EPS | 1.40571 | 0.30269 | 2.05388 | 1.20794 | 1.37668 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 14772 | 15996 | 30296 | 35836 | 31823 |
| Raha ja lühiajalised investeeringud | 6520 | 7408 | 24352 | 30089 | 25510 |
| Raha ja ekvivalendid | 5338 | 5997 | 11631 | 17940 | 7588 |
| Lühiajalised investeeringud | 1182 | 1411 | 12721 | 12149 | 17922 |
| Laekumata arved, neto | 4493 | 4892 | 3582 | 3327 | 3851 |
| Accounts Receivable - Trade, Net | 4493 | 4892 | 3582 | 3327 | 3851 |
| Total Inventory | 1618 | 1683 | 922 | 814 | 801 |
| Prepaid Expenses | 2141 | 2013 | 1403 | 1533 | 1649 |
| Total Assets | 67952 | 68407 | 61627 | 63675 | 70283 |
| Property/Plant/Equipment, Total - Net | 5663 | 5613 | 5170 | 4006 | 3295 |
| Goodwill, Net | 8332 | 8108 | 4117 | 4117 | 4159 |
| Intangibles, Net | 33455 | 33126 | 13786 | 15738 | 17100 |
| Long Term Investments | 1309 | 502 | 1488 | 1423 | 11194 |
| Other Long Term Assets, Total | 4421 | 5062 | 6770 | 2555 | 2712 |
| Total Current Liabilities | 11610 | 11397 | 9759 | 10605 | 11635 |
| Accounts Payable | 705 | 844 | 713 | 790 | 814 |
| Accrued Expenses | 7600 | 7198 | 6254 | 6876 | 7271 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1516 | 2757 | 2499 | 2748 | 2747 |
| Other Current Liabilities, Total | 1789 | 598 | 293 | 191 | 803 |
| Total Liabilities | 46883 | 50205 | 39102 | 42288 | 49841 |
| Total Long Term Debt | 25179 | 28645 | 22094 | 24574 | 30795 |
| Long Term Debt | 25179 | 28645 | 22094 | 24574 | 30795 |
| Minority Interest | -5 | 19 | 125 | 147 | 59 |
| Other Liabilities, Total | 5743 | 10144 | 7124 | 6962 | 7352 |
| Total Equity | 21069 | 18202 | 22525 | 21387 | 20442 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 4661 | 3880 | 3051 | 2282 | 1264 |
| Retained Earnings (Accumulated Deficit) | 16324 | 14381 | 19388 | 19024 | 19012 |
| Unrealized Gain (Loss) | -4 | 2 | 1 | -52 | 194 |
| Other Equity, Total | 87 | -62 | 84 | 132 | -29 |
| Total Liabilities & Shareholders’ Equity | 67952 | 68407 | 61627 | 63675 | 70283 |
| Total Common Shares Outstanding | 1254 | 1254 | 1266 | 1282 | 1308 |
| Other Current Assets, Total | 37 | 73 | 12 | ||
| Property/Plant/Equipment, Total - Gross | 7556 | 7281 | 6592 | 5197 | 4289 |
| Accumulated Depreciation, Total | -1893 | -1668 | -1422 | -1191 | -994 |
| Deferred Income Tax | 4356 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 12629 | 14772 | 13991 | 13925 | 13278 |
| Raha ja lühiajalised investeeringud | 5325 | 6520 | 5738 | 6525 | 5666 |
| Raha ja ekvivalendid | 4296 | 5338 | 4362 | 4893 | 4065 |
| Lühiajalised investeeringud | 1029 | 1182 | 1376 | 1632 | 1601 |
| Laekumata arved, neto | 3787 | 4493 | 4566 | 4149 | 3925 |
| Accounts Receivable - Trade, Net | 3787 | 4493 | 4566 | 4149 | 3925 |
| Total Inventory | 1482 | 1618 | 1676 | 1772 | 1779 |
| Prepaid Expenses | 2035 | 2141 | 2011 | 1479 | 1908 |
| Total Assets | 63080 | 67952 | 67098 | 67984 | 67492 |
| Property/Plant/Equipment, Total - Net | 5253 | 5121 | 5037 | 4996 | 4990 |
| Goodwill, Net | 8314 | 8332 | 8332 | 8334 | 8334 |
| Intangibles, Net | 30331 | 33455 | 33900 | 34341 | 34781 |
| Long Term Investments | 1427 | 1309 | 1099 | 836 | 579 |
| Other Long Term Assets, Total | 5126 | 4963 | 4739 | 5552 | 5530 |
| Total Current Liabilities | 8558 | 11610 | 10245 | 10214 | 9705 |
| Accounts Payable | 583 | 705 | 585 | 608 | 570 |
| Accrued Expenses | 6483 | 7600 | 6702 | 6906 | 6661 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1025 | 1516 | 2511 | 2261 | 2259 |
| Other Current Liabilities, Total | 467 | 1789 | 447 | 439 | 215 |
| Total Liabilities | 43153 | 46883 | 45628 | 48281 | 48540 |
| Total Long Term Debt | 25183 | 25179 | 25175 | 27914 | 27907 |
| Long Term Debt | 25183 | 25179 | 25175 | 27914 | 27907 |
| Deferred Income Tax | 3687 | 4356 | 4603 | 4374 | 4464 |
| Minority Interest | -12 | -5 | 1 | 7 | 12 |
| Other Liabilities, Total | 5737 | 5743 | 5604 | 5772 | 6452 |
| Total Equity | 19927 | 21069 | 21470 | 19703 | 18952 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 4867 | 4661 | 4492 | 4271 | 4092 |
| Retained Earnings (Accumulated Deficit) | 14986 | 16324 | 16903 | 15392 | 14821 |
| Unrealized Gain (Loss) | -23 | -4 | -1 | -1 | 0 |
| Other Equity, Total | 96 | 87 | 75 | 40 | 38 |
| Total Liabilities & Shareholders’ Equity | 63080 | 67952 | 67098 | 67984 | 67492 |
| Total Common Shares Outstanding | 1255 | 1254 | 1255 | 1254 | 1254 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | 6201 | 89 | 5364 | 5460 | 4644 |
| Raha majandustegevusest | 11384 | 8168 | 9144 | 8400 | 11898 |
| Raha majandustegevusest | 329 | 288 | 255 | 226 | 233 |
| Amortization | 1721 | 1192 | 1149 | 1203 | 1053 |
| Deferred Taxes | -116 | -214 | -2098 | 289 | -82 |
| Mittelikviidsed varad | 2760 | 8451 | 5272 | 2161 | 942 |
| Cash Taxes Paid | 2509 | 2639 | 1793 | 3198 | 3342 |
| Makstud intressid | 979 | 951 | 982 | 1070 | 1038 |
| Muutused tööjõus | 489 | -1638 | -798 | -939 | 5108 |
| Tulu investeeringutelt | -3131 | -14615 | -7817 | 14355 | -16069 |
| Kapitalikulutused | -579 | -650 | -825 | -924 | -590 |
| Muud rahavood investeeringutelt, kokku | -2552 | -13965 | -6992 | 15279 | -15479 |
| Rahavood investeeringutelt | -8877 | 770 | -7634 | -12318 | 3393 |
| Rahavoogudesse investeerimine | -145 | -138 | -122 | -486 | -330 |
| Total Cash Dividends Paid | -3605 | -3449 | -3222 | -2971 | -2731 |
| Aktsiate emiteerimine (tagasiost), neto | -377 | -1327 | -1540 | -2611 | -720 |
| Laenu väljastamine (kustutamine), neto | -4750 | 5684 | -2750 | -6250 | 7174 |
| Muutused valuutakursside kõikumisest | -35 | 43 | -2 | -85 | 137 |
| Rahaline kogumuutus | -659 | -5634 | -6309 | 10352 | -641 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 12 | 6201 | 5825 | 3239 | 1722 |
| Cash From Operating Activities | 1840 | 11384 | 8179 | 4926 | 2610 |
| Cash From Operating Activities | 80 | 329 | 239 | 157 | 78 |
| Amortization | 445 | 1721 | 1276 | 835 | 395 |
| Deferred Taxes | -651 | -116 | 243 | 3 | 71 |
| Non-Cash Items | 3116 | 2760 | 1921 | 1564 | 753 |
| Changes in Working Capital | -1162 | 489 | -1325 | -872 | -409 |
| Cash From Investing Activities | -1070 | -3131 | -2853 | -2619 | -2042 |
| Capital Expenditures | -247 | -579 | -423 | -284 | -165 |
| Other Investing Cash Flow Items, Total | -823 | -2552 | -2430 | -2335 | -1877 |
| Cash From Financing Activities | -1794 | -8877 | -6935 | -3408 | -2477 |
| Financing Cash Flow Items | -91 | -145 | -134 | -95 | -89 |
| Total Cash Dividends Paid | -945 | -3605 | -2711 | -1811 | -917 |
| Issuance (Retirement) of Stock, Net | -258 | -377 | -340 | -252 | -221 |
| Issuance (Retirement) of Debt, Net | -500 | -4750 | -3750 | -1250 | -1250 |
| Foreign Exchange Effects | -18 | -35 | -26 | -3 | -23 |
| Net Change in Cash | -1042 | -659 | -1635 | -1104 | -1932 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.9329 | 111403199 | -68465 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.025 | 87609319 | 3078449 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 5.5242 | 68892972 | 11130228 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.7263 | 58941373 | -298977 | 2022-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 4.3784 | 54602952 | 727482 | 2022-12-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 2.8775 | 35885152 | -484100 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9123 | 23848477 | 244886 | 2022-12-31 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.3088 | 16322394 | 84245 | 2023-02-28 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.224 | 15265179 | 12533445 | 2022-12-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 1.1113 | 13859234 | 761084 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0416 | 12989939 | -106202 | 2022-12-31 | LOW |
| Parnassus Investments, LLC | Investment Advisor | 0.9672 | 12062537 | 295282 | 2022-12-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8569 | 10686823 | -393685 | 2022-12-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7805 | 9733453 | -126327 | 2022-12-31 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.7772 | 9693019 | -93438 | 2022-12-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7531 | 9391729 | -99918 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.7379 | 9202568 | -820000 | 2022-12-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7195 | 8972729 | -116113 | 2022-12-31 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.692 | 8630001 | -344541 | 2022-12-31 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.6788 | 8465274 | -377056 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Gilead Company profile
Ettevõttest Gilead Sciences
Gilead Sciences, Inc. on biofarmatseutiline ettevõte. Ettevõte keskendub ravimite avastamisele, arendamisele ja turustamisele haiguste, sealhulgas inimese immuunpuudulikkuse viiruse (HIV), viirushepatiidi ja vähi ennetamiseks ja raviks. Ettevõtte HIV/AIDSi patsientidele mõeldud toodete hulka kuuluvad Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild ja Atripla. COVID-19 toode on Veklury. Maksahaiguste ravimite hulka kuuluvad Epclusa, Harvoni, Vosevi, Vemlidy ja Viread. Hematoloogia/onkoloogia/rakuteraapia toodete hulka kuuluvad Yescarta, Tecartus, Trodelvy ja Zydelig. Muude toodete hulka kuuluvad Letairis (ambrisentaan), Ranexa (ranolasiin), Cayston, Jyseleca ja AmBisome (amfoteritsiin B liposoom süstimiseks). Ettevõte müüb ja turustab Ameerika Ühendriikides ka Epclusa ja Harvoni geneerilisi versioone. Ettevõte müüb ja turustab oma tooteid Ameerika Ühendriikides hulgimüügikanali kaudu. Ettevõte tegutseb rohkem kui 35 riigis kogu maailmas.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com